Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Senescence cell–associated extracellular vesicles serve as osteoarthritis disease and therapeutic markers
Ok Hee Jeon, … , Kenneth W. Witwer, Jennifer H. Elisseeff
Ok Hee Jeon, … , Kenneth W. Witwer, Jennifer H. Elisseeff
Published April 4, 2019
Citation Information: JCI Insight. 2019;4(7):e125019. https://doi.org/10.1172/jci.insight.125019.
View: Text | PDF
Research Article Aging Therapeutics

Senescence cell–associated extracellular vesicles serve as osteoarthritis disease and therapeutic markers

  • Text
  • PDF
Abstract

Senescent cells (SnCs) are increasingly recognized as central effector cells in age-related pathologies. Extracellular vesicles (EVs) are potential cellular communication tools through which SnCs exert central effector functions in the local tissue environment. To test this hypothesis in a medical indication that could be validated clinically, we evaluated EV production from SnCs enriched from chondrocytes isolated from human arthritic cartilage. EV production increased in a dose-responsive manner as the concentration of SnCs increased. The EVs were capable of transferring senescence to nonsenescent chondrocytes and inhibited cartilage formation by non-SnCs. microRNA (miR) profiles of EVs isolated from human arthritic synovial fluid did not fully overlap with the senescent chondrocyte EV profiles. The effect of SnC clearance was tested in a murine model of posttraumatic osteoarthritis. miR and protein profiles changed after senolytic treatment but varied depending on age. In young animals, senolytic treatment altered expression of miR-34a, -30c, -125a, -24, -92a, -150, and -186, and this expression correlated with cartilage production. The primary changes in EV contents in aged mice after senolytic treatment, which only reduced pain and degeneration, were immune related. In sum, EV contents found in synovial fluid may serve as a diagnostic for arthritic disease and indicator for therapeutic efficacy of senolytic treatment.

Authors

Ok Hee Jeon, David R. Wilson, Cristina C. Clement, Sona Rathod, Christopher Cherry, Bonita Powell, Zhenghong Lee, Ahmad M. Khalil, Jordan J. Green, Judith Campisi, Laura Santambrogio, Kenneth W. Witwer, Jennifer H. Elisseeff

×

Figure 2

Decreased secretion of EVs from human OA chondrocytes after removing SnCs and alteration in miRs carried by synovial EVs from OA patients.

Options: View larger image (or click on image) Download as PowerPoint
Decreased secretion of EVs from human OA chondrocytes after removing SnC...
(A) Representative electron micrographs of EVs derived from OA chondrocytes treated with vehicle (veh) and UBX0101. Scale bar: 200 nm. (B and C) Mean size and concentration of EV enrichments released per cell in human OA chondrocytes at 1, 2, 4, and 6 days after incubation with veh or 43 μM UBX0101, measured by nanoparticle tracking analysis (n = 3 per data point). The experiment was performed 2 independent times. Data are shown as mean ± SEM. Statistical analysis was performed using 2-tailed t tests (unpaired). **P < 0.01, ***P < 0.001. (D) Heatmap and hierarchical clustering depicting statistically significant (P < 0.1 by t test) differentially expressed miRs. Synovial fluid was obtained from normal (Nor) individuals (age 77.3 ± 6.8 years; n = 3) and OA patients (age 64.5 ± 2.1 years; n = 2). PC, predicted candidate.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts